Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

about

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.Management of functional neuroendocrine tumors of the pancreas.

P2860

Q38956091-ED2F7A59-68D4-45F3-80B9-5D8BF73E19EE Q47097042-F5A278C0-B3CD-4163-9FD8-6EF4435F33C3 Q52599451-06841123-638B-412D-A20A-0E22CC0C7BB5

P2860

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

Item

http://www.wikidata.org/entity/Q36637525

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@ast

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@en

type

Item

label

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@ast

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@en

prefLabel

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@ast

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@en

P1476

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

@en

P2093

Andreas G Moraitis

http://www.w3.org/2001/XMLSchema#string

Richard J Auchus

http://www.w3.org/2001/XMLSchema#string

P2860

Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.

Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH-producing carcinoid tumours.

Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.

Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small cell lung cancer.

The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.

P304

8453801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/8453801

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294878593

http://www.w3.org/2001/XMLSchema#string

P698

26989527

http://www.w3.org/2001/XMLSchema#string

P932

4773543

http://www.w3.org/2001/XMLSchema#string

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

about

P2860

P2860

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932